Cassava Sciences | PTIE - Equity Capital And Reserves


Cassava Sciences reported $68.14M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Cassava Sciences USD 68.14M 6.26M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Geron USD 229.11M 3.24M Mar/2026
J&J USD 81.19B 358M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025